Promising Research

 
Stock Quotes for Promising Research top ^
  • Industry: Data Storage
  • Sector: Technology
  • Stock Style: Small Growth
Sign-up for 3057 investment picks

 
News Articles for Promising Research top ^
2014/10/1
Today, a national program that helps temporarily homeless families keep all members of their family together – including their four-legged family members - is celebrating the two year anniversary of the program’s launch in Phoenix.
Sign-up for Family Promise of Greater Phoenix and PetSmart Celebrate Two Years of PetSmart Promise investment picks
By Michael Calia Chimerix Inc. said Wednesday that an experimental drug that has been used to treat an Ebola patient demonstrated improved survival for patients suffering from another ailment.
Sign-up for Chimerix Ebola drug shows promise for another ailment investment picks
2014/10/6
Sam’s Club announced today that the flu shots for the 2014-2015 flu season are now available to Sam’s Club members as well as the public at pharmacy locations nationwide.
Sign-up for Sam’s Club® Helps Members and the Public Prepare for Upcoming Flu Season with Low Price Promise investment picks
NCR Corporation (NYSE: NCR), the global leader in consumer transaction technologies, announced today that it has successfully deployed the NCR venue management solution at Ascot Racecourse, ‘the grand old lady’ of Australian racecourses.
Sign-up for Ascot Racecourse Promises Exceptional Customer Experiences with NCR Venue Management Solution investment picks
SALT LAKE CITY , Nov.
Sign-up for Dynatronics Announces Promising First Quarter Financial Results investment picks
Cytori Therapeutics, Inc. (NASDAQ: CYTX) today reported positive results from a clinical study of Cytori Cell Therapy™ in anterior cruciate ligament (ACL) reconstruction of patients with ACL tears.
Sign-up for Cytori Announces Promising Results in a Feasibility Trial of Cytori Cell Therapy in Conjunction with Anterior Cruciate Ligament Repair investment picks
2014/12/6
- Note: This press release corresponds to abstract 31.
Sign-up for IMBRUVICA® (ibrutinib) Data Suggests Promise in Multiple Myeloma investment picks
By Ron Winslow SAN FRANCISCO--Four patients with a lethal blood disorder were able to forgo life-sustaining blood transfusions within 90 days after they were treated with a technique to replace the defective gene responsible for their disease, researchers said Monday.
Sign-up for Bluebird gene therapy shows promise for lethal blood disease investment picks
Foundation Medicine, Inc. (NASDAQ:FMI) today announced new data demonstrating that its comprehensive genomic profile, FoundationOne® Heme , identified genomic alterations in patients with heavily pre-treated multiple myeloma that informed treatment with trametinib, an FDA-approved targeted therapeutic agent 1 .
Sign-up for Treatment for Relapsed Multiple Myeloma Patients Guided by FoundationOne® Heme Results in Promising Clinical Activity investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Promising Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Promising Companies  |  Next: Promote Research